search
Back to results

Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) (MICCHADO)

Primary Purpose

Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family of Tumors

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Sampling on blood, bone marrow and cerebrospinal fluid
Sponsored by
Institut Curie
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Neuroblastoma

Eligibility Criteria

1 Year - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Inclusion within 3 months after diagnosis
  2. Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure
  3. Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients)
  4. Age: ≤ 25 years at diagnosis
  5. Written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent
  6. Compulsory affiliation to a social security scheme

    Additional inclusion criteria for the study:

    To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis.

    Cohort 1:

    • High risk neuroblastoma:

      - Any type of neuroblastoma with MYCN amplification, except INSS stage 1

      - Stage 4 neuroblastoma in children older than one year at diagnosis

    • High risk rhabdomyosarcoma:

      • Foxo1 rearrangement any stage;
      • and / or N1 ;
      • and / or metastatic rhabdomyosarcoma
    • High risk Ewing sarcoma:

      • Metastatic Ewing sarcoma family of tumours (ESFT)
      • Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml
    • High risk osteosarcoma:

      - Metastatic osteosarcoma

      - Localised inoperable osteosarcoma

    • High risk leukaemia:

      • Secondary acute myeloid leukaemia
      • Biphenotypic acute leukaemia

    Cohort 2:

    • Extra cerebral or cerebral high risk tumours including:

    • other metastatic sarcomas,
    • other rare high risk cancers,
    • high risk renal tumours with surgery after an initial chemotherapy
    • rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours
    • high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute lymphoblastic leukaemia:
    • MRD ≥ 10-2 at the end of the induction ;
    • or MRD ≥ 10-3 at Day 78

    Cohort 3:

    Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types:

    • Neuroblastoma:

    - Localised, without MYCN amplification

    • Localised, INSS stage 1, with MYCN amplification
    • Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification

      • Rhabdomyosarcoma:

    • Localised, without Foxo1 rearrangement

      • ESFT:

    • All non-high risk localised ESFT • Osteosarcoma:
    • All non-high risk localised osteosarcoma

    Exclusion Criteria:

    Main non-inclusion Criteria common to all study cohorts:

1) Age: patients > 25 years old at diagnosis 2) Absence of patient or parents or legal representative written informed consent 3) Patient for whom follow-up by the investigating centre does not appear feasible

Sites / Locations

  • Chu D'Amiens Picardie
  • CHU AngersRecruiting
  • CHRU de Besançon - Hôpital Jean-Minjoz
  • CHU de Bordeaux - Hôpital des enfants - Groupe Hospitalier PellegrinRecruiting
  • CHRU de BrestRecruiting
  • CHU CAENRecruiting
  • Centre Régional de Cancérologie et Thrapie Cellulaire Pdiatrique (CRCTCP)Recruiting
  • CHU Hôpital d'Enfants
  • CHU GRENOBLE Alpes - Hôpital Couple-EnfantRecruiting
  • Centre Oscar LambretRecruiting
  • CHU de Limoges - Hôpital Mère-Enfant
  • Centre Léon BérardRecruiting
  • Hospices Civils de Lyon
  • Hôpital d'Enfants de la Timone (AP-HM)Recruiting
  • CHU Arnaud de VilleneuveRecruiting
  • CHU Nantes - Hôpital Mère Enfant
  • Hôpital l'Archet 2Recruiting
  • Hôpital d'Enfants Armand-TrousseauRecruiting
  • Hôpital universitaire Robert-Debré (AP-HP)Recruiting
  • Institut CurieRecruiting
  • CHU de PoitiersRecruiting
  • CHU de Reims - Hôpital Américain
  • Chu Hopital Sud RennesRecruiting
  • CHU de Rouen - Hôp. Charles NICOLLERecruiting
  • CHU Saint-Etienne - Hôpital Nord
  • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
  • CHU Hôpital des EnfantsRecruiting
  • CHU TOURS - Hôpital ClochevilleRecruiting
  • CHU Nancy - Hôpital d'EnfantsRecruiting
  • Gustave RoussyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

High risk Cohorts

Low risk Cohort

Arm Description

Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid

Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid

Outcomes

Primary Outcome Measures

Number of patients with meaningful molecular genetic alterations
Identification of molecular genetic alterations based on molecular characterisation of tumor at diagnosis, during patient treatment and follow-up (time dimension)
Number of patients with meaningful immunological features
Identification and characterisation of the tumor microenvironment and the host's immunological profile, at diagnosis and during patient treatment
Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)
Comparison between genetic variations identified at diagnosis and those identified on circulating tumor DNA during treatment, FU and/or relapse

Secondary Outcome Measures

Correlation between disease recurrence and molecular and/or immunological biomarkers
To characterise biomarkers, based on molecular analyses of tumour samples from diagnosis, for prognostic and predictive purposes. To characterise the tumour microenvironment and the host's immunological profile, for prognostic and predictive purposes. To identify potential prognostic and predictive biomarkers on samples collected during patient's treatment and follow-up, based on changes on circulating tumour DNA (ctDNA), detected by molecular biology techniques, and on immunological findings
Correlation between genetic variations and immune parameters
To compare molecular and immunological findings at diagnosis and during treatment (data integration)
Correlation between disease staging and immunological features
To investigate the impact of the tumour microenvironment and host's immunological profile on the disease staging at diagnosis, by comparing patients with metastatic to patients with localised disease

Full Information

First Posted
February 26, 2018
Last Updated
October 24, 2023
Sponsor
Institut Curie
search

1. Study Identification

Unique Protocol Identification Number
NCT03496402
Brief Title
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
Acronym
MICCHADO
Official Title
Molecular and Immunological Characterisation of High Risk CHildhood Cancer At DiagnOsis, Treatment and Follow-up - Biological Evaluation in Children, Adolescents and Young Adults -
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 20, 2018 (Actual)
Primary Completion Date
September 24, 2026 (Anticipated)
Study Completion Date
July 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Curie

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Methodology: Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study
Detailed Description
To identify and characterise: meaningful molecular genetic alterations, meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family of Tumors, Osteosarcoma, Leukemia, Central Nervous System Tumor

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
High risk Cohorts
Arm Type
Experimental
Arm Description
Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
Arm Title
Low risk Cohort
Arm Type
Experimental
Arm Description
Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
Intervention Type
Other
Intervention Name(s)
Sampling on blood, bone marrow and cerebrospinal fluid
Intervention Description
biological sampling during treatment and follow-up
Primary Outcome Measure Information:
Title
Number of patients with meaningful molecular genetic alterations
Description
Identification of molecular genetic alterations based on molecular characterisation of tumor at diagnosis, during patient treatment and follow-up (time dimension)
Time Frame
At the end of study (6 years)
Title
Number of patients with meaningful immunological features
Description
Identification and characterisation of the tumor microenvironment and the host's immunological profile, at diagnosis and during patient treatment
Time Frame
At the end of study (6 years)
Title
Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)
Description
Comparison between genetic variations identified at diagnosis and those identified on circulating tumor DNA during treatment, FU and/or relapse
Time Frame
up to 6 years
Secondary Outcome Measure Information:
Title
Correlation between disease recurrence and molecular and/or immunological biomarkers
Description
To characterise biomarkers, based on molecular analyses of tumour samples from diagnosis, for prognostic and predictive purposes. To characterise the tumour microenvironment and the host's immunological profile, for prognostic and predictive purposes. To identify potential prognostic and predictive biomarkers on samples collected during patient's treatment and follow-up, based on changes on circulating tumour DNA (ctDNA), detected by molecular biology techniques, and on immunological findings
Time Frame
up to 6 years
Title
Correlation between genetic variations and immune parameters
Description
To compare molecular and immunological findings at diagnosis and during treatment (data integration)
Time Frame
up to 6 years
Title
Correlation between disease staging and immunological features
Description
To investigate the impact of the tumour microenvironment and host's immunological profile on the disease staging at diagnosis, by comparing patients with metastatic to patients with localised disease
Time Frame
up to 6 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Inclusion within 3 months after diagnosis Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients) Age: ≤ 25 years at diagnosis Written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent Compulsory affiliation to a social security scheme Additional inclusion criteria for the study: To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis. Cohort 1: High risk neuroblastoma: - Any type of neuroblastoma with MYCN amplification, except INSS stage 1 - Stage 4 neuroblastoma in children older than one year at diagnosis High risk rhabdomyosarcoma: Foxo1 rearrangement any stage; and / or N1 ; and / or metastatic rhabdomyosarcoma High risk Ewing sarcoma: Metastatic Ewing sarcoma family of tumours (ESFT) Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml High risk osteosarcoma: - Metastatic osteosarcoma - Localised inoperable osteosarcoma High risk leukaemia: Secondary acute myeloid leukaemia Biphenotypic acute leukaemia Cohort 2: • Extra cerebral or cerebral high risk tumours including: other metastatic sarcomas, other rare high risk cancers, high risk renal tumours with surgery after an initial chemotherapy rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute lymphoblastic leukaemia: MRD ≥ 10-2 at the end of the induction ; or MRD ≥ 10-3 at Day 78 Cohort 3: Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types: • Neuroblastoma: - Localised, without MYCN amplification Localised, INSS stage 1, with MYCN amplification Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification • Rhabdomyosarcoma: Localised, without Foxo1 rearrangement • ESFT: All non-high risk localised ESFT • Osteosarcoma: All non-high risk localised osteosarcoma Exclusion Criteria: Main non-inclusion Criteria common to all study cohorts: 1) Age: patients > 25 years old at diagnosis 2) Absence of patient or parents or legal representative written informed consent 3) Patient for whom follow-up by the investigating centre does not appear feasible
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gudrun SCHLEIERMACHER, MD
Phone
+33(0)144324554
Email
gudrun.schleiermacher@curie.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Christine FOULON
Phone
+33(0)147111733
Email
christine.foulon@curie.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gudrun SCHLEIERMACHER, MD
Organizational Affiliation
Institut Curie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chu D'Amiens Picardie
City
Amiens
ZIP/Postal Code
80054
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catherine DEVOLDERE, MD
Email
devoldere.catherine@chu-amiens.fr
Facility Name
CHU Angers
City
Angers
ZIP/Postal Code
49933
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle PELLIER, MD
Phone
(+33) 02.41.35.38.63
Email
ispellier@chu-angers.fr
Facility Name
CHRU de Besançon - Hôpital Jean-Minjoz
City
Besançon
ZIP/Postal Code
25030
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastien KLEIN, MD
Phone
(+33) 03 81 21 81 38
Email
s1klein@chu-besancon.fr
Facility Name
CHU de Bordeaux - Hôpital des enfants - Groupe Hospitalier Pellegrin
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane DUCASSOU, MD
Phone
05 57 82 04 38
Email
stephane.ducassou@chu-bordeaux.fr
Facility Name
CHRU de Brest
City
Brest
ZIP/Postal Code
29609
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liana-Stéphania CARAUSU, MD
Phone
(+33) 02 98 22 37 70
Email
liana.carausu@chu-brest.fr
Facility Name
CHU CAEN
City
Caen
ZIP/Postal Code
14033
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marianna DEPARIS, MD
Phone
(+33) 02 31 06 50 82
Email
deparis-m@chu-caen.fr
Facility Name
Centre Régional de Cancérologie et Thrapie Cellulaire Pdiatrique (CRCTCP)
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justyna KANOLD, MD
Phone
(+33) 04 73 75 00 09
Email
jkanold@chu-clermontferrand.fr
Facility Name
CHU Hôpital d'Enfants
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire BRIANDET, MD
Phone
(+33) 03 80 29 36 01
Email
claire.briandet@chu-dijon.fr
Facility Name
CHU GRENOBLE Alpes - Hôpital Couple-Enfant
City
Grenoble
ZIP/Postal Code
38043
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cécile PERRET, MD
Phone
(+33) 04 76 76 89 11
Email
cperret1@chu-grenoble.fr
Facility Name
Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne-Sophie DEFACHELLESTHOMASSIN, MD
Phone
(+33) 03 20 59 06
Email
AS-Defachelles@o-lambret.fr
Facility Name
CHU de Limoges - Hôpital Mère-Enfant
City
Limoges
ZIP/Postal Code
87042
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe PIGUET, MD
Phone
(+33) 05 55 05 68 01
Email
christophe.piguet@chu-limoges.fr
Facility Name
Centre Léon Bérard
City
Lyon
ZIP/Postal Code
69373
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nadège CORRADINI, MD
Phone
(+33) 04 78 78 26 42
Email
Nadege.corradini@ihope.fr
Facility Name
Hospices Civils de Lyon
City
Lyon
ZIP/Postal Code
69373
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yves BERTRAND, MD
Phone
(+33) 04 69 16 65 70
Email
Yves.bertrand@ihope.fr
Facility Name
Hôpital d'Enfants de la Timone (AP-HM)
City
Marseille
ZIP/Postal Code
13385
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carole COZE, MD
Email
carole.coze@ap-hm.fr
Facility Name
CHU Arnaud de Villeneuve
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laure SAUMET, MD
Phone
(+33) 04 67 33 65 19
Email
l-saumet@chu-montpellier.fr
Facility Name
CHU Nantes - Hôpital Mère Enfant
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Estelle THEBAUD, MD
Email
estelle.thebaud@chu-nantes.fr
Facility Name
Hôpital l'Archet 2
City
Nice
ZIP/Postal Code
BP 3079
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre-Simon ROHRLICH, MD
Phone
(+33) 04 92 03 92 68
Email
rohrlich.ps@chu-nice.fr
Facility Name
Hôpital d'Enfants Armand-Trousseau
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arnaud PETIT, MD
Phone
(+33) 01.71.73.82.57
Email
arnaud.petit@trs.aphp.fr
Facility Name
Hôpital universitaire Robert-Debré (AP-HP)
City
Paris
ZIP/Postal Code
75019
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
André BARUCHEL, MD
Phone
(+33) 01 40 03 53 88
Email
andre.baruchel@aphp.fr
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
750248
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gudrun SCHLEIERMACHER, MD
Phone
+ 00 33 (0)1.44.32.45.51
Email
gudrun.schleiermacher@curie.fr
Facility Name
CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric MILLOT, MD
Phone
(+33) 05.49.44.30.78
Email
f.millot@chu-poitiers.fr
Facility Name
CHU de Reims - Hôpital Américain
City
Reims
ZIP/Postal Code
51100
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire PLUCHART, MD
Phone
(+33) 03 26 78 41 54
Email
cpluchart@chu-reims.fr
Facility Name
Chu Hopital Sud Rennes
City
Rennes
ZIP/Postal Code
35056
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie TAQUE, MD
Phone
(+33) 02 99 26 58 35
Email
sophie.taque@chu-rennes.fr
Facility Name
CHU de Rouen - Hôp. Charles NICOLLE
City
Rouen
ZIP/Postal Code
76031
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascale SCHNEIDER, MD
Phone
(+33) 02 32 88 81 91
Email
pascale.schneider@chu-rouen.fr
Facility Name
CHU Saint-Etienne - Hôpital Nord
City
Saint-Étienne
ZIP/Postal Code
42055
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Audrey DAVID, MD
Phone
(+33) 04 77 82 88 08
Email
audrey.david@chu-st-etienne.fr
Facility Name
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catherine PAILLARD, MD
Phone
(+33) 03.88.12.80.91
Email
catherine.paillard@chru-strasbourg.fr
Facility Name
CHU Hôpital des Enfants
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marion GAMBART, MD
Phone
(+33) 05 34 55 84 26
Email
gambart.m@chu-toulouse.fr
Facility Name
CHU TOURS - Hôpital Clocheville
City
Tours
ZIP/Postal Code
37044
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascale BLOUIN, MD
Phone
(+33) 02 47 47 47 51
Email
p.blouin@chu-tours.fr
Facility Name
CHU Nancy - Hôpital d'Enfants
City
Vandoeuvre les Nancy
ZIP/Postal Code
54500
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascal CHASTAGNER, MD
Phone
(+33) 03 83 15 47 36
Email
p.chastagner@chru-nancy.fr
Facility Name
Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudia PASQUALINI, MD
Phone
(+33) 01 42 11 37 58
Email
Claudia.PASQUALINI@gustaveroussy.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)

We'll reach out to this number within 24 hrs